Description
Key facts
Purity:>90% SDS-PAGE,
Expression system:Yeast,
Tags:His tag N-Terminus,
Applications:SDS-PAGE, Mass SpecSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Biologically active:No,
Accession:Q9NYJ7,
Animal free:No,
Carrier free:No,
Species:Human,
Storage buffer:pH: 7.2 - 7.4Constituents: Tris buffer, 50% Glycerol (glycerin, glycerine)
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Avoid freeze / thaw cycle
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DLL3 also known as Delta-like protein 3 is a member of the Delta/Serrate/Jagged family. This protein has a molecular mass of approximately 64 kDa. Scientists find DLL3 expression primarily in the Golgi apparatus of cells. In healthy tissues DLL3 is mostly present in the central nervous system whereas in abnormal conditions it appears in certain types of cancer cells. The detection of DLL3 expression commonly performed using IHC (immunohistochemistry) highlights its potential as a biomarker in pathological studies.
Biological function summary
DLL3 functions mainly in the modulation of the Notch signaling pathway. It does not activate this pathway but acts as an inhibitor blocking Notch ligand activation on adjacent cells. DLL3's role involves binding directly to Notch receptors altering cellular differentiation and growth processes. Despite being related to the Delta/Serrate/LAG-2 family DLL3 exhibits unique characteristics in its interactions forming part of a regulatory complex different from its family members.
Pathways
DLL3 engages importantly in the Notch signaling pathway affecting important cellular communications that regulate development and differentiation. Its interaction with proteins of the Notch family specifically the Notch receptors highlights its inhibitory role. Additionally DLL3 intersects with the Wnt signaling pathway though indirect influencing its output by modulating availability of pathway regulators.
DLL3 has significant implications in cancer notably small cell lung cancer (SCLC) and neuroendocrine tumors. Researchers associate increased DLL3 expression with aggressive tumor behavior and poor prognosis. The protein also shows relevance in congenital disorders such as spondylocostal dysostosis where abnormal DLL3 function leads to vertebral segmentation defects. In these contexts DLL3 often relates to proteins involved in the disruption of normal signaling cascades impacting both tumor progression and developmental anomalies.
